5 completed, 4 terminated, 1 recruiting, 1 withdrawn. 7 Phase 1, 6 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 4, Terminated 3 |
| Phase 2 | 6 | Completed 2, Terminated 2, Recruiting 1, Withdrawn 1 |
| Phase 3 | 1 | Completed 1 |
Follow Elevar Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement Lirafugratinib - FGFR2 Gene Fusion/Rearrangement, Other Solid Tumors, Adult | Phase 2 | Recruiting | Elevar Therapeutics | 30 | 2026-06-04 | 2026-11-09 |
| A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma Rivoceranib - Metastatic Olfactory Neuroblastoma, Recurrent Olfactory Neuroblastoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2024-11-01 | 2025-01-10 | |
| A Study Comparing Four Different Rivoceranib Tablets in Healthy Participants Rivoceranib - Healthy | Phase 1 | Completed | Elevar Therapeutics | 60 | 2021-12-30 | 2022-04-18 |
| REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors RLY-4008 - FGFR2 Amplification, FGFR2 Gene Mutation | Phase 1 / Phase 2 | Completed | Elevar Therapeutics | 490 | 2020-09-02 | 2026-02-27 |
| A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC) Rivoceranib - Adenoid Cystic Carcinoma | Phase 2 | Terminated | Elevar Therapeutics | 80 | 2020-01-22 | 2026-07-30 |
| A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC) Rivoceranib, Trifluridine/Tipiracil - Metastatic Colorectal Cancer | Phase 1 | Terminated | Elevar Therapeutics | 29 | 2019-11-18 | 2024-05-02 |
| A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer Rivoceranib, Paclitaxel - Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 1 / Phase 2 | Terminated | Elevar Therapeutics | 12 | 2018-10-01 | 2022-04-11 |
| Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies Apatinib, Pembrolizumab - Advanced Malignancies, Urothelial Carcinoma | Phase 1 | Terminated | University of Utah | 5 | 2018-06-19 | 2020-07-15 |
| A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer Apatinib, Nivolumab - Cancer | Phase 1 | Completed | Elevar Therapeutics | 30 | 2017-12-22 | 2023-04-07 |
| A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer Rivoceranib, Placebo - Gastric Cancer, Gastric Adenocarcinoma | Phase 3 | Completed | Elevar Therapeutics | 460 | 2017-03-14 | 2022-07-08 |
| Dose-Escalation and Safety Trial of YN968D1 YN968D1 - Cancer Patients With Solid Tumors | Phase 1 / Phase 2 | Completed | Elevar Therapeutics | 55 | 2012-04-01 | 2017-10-02 |
Neoplasms (3) · Neoplasm Metastasis (2) · Stomach Neoplasms (2) · Adenocarcinoma (1) · Carcinoma, Adenoid Cystic (1) · Carcinoma, Transitional Cell (1) · Cholangiocarcinoma (1) · Colorectal Neoplasms (1) · Esthesioneuroblastoma, Olfactory (1)
apatinib (9) · Nivolumab (1) · Paclitaxel (1) · pembrolizumab (1) · trifluridine tipiracil drug combination (1)
United States (9) · South Korea (6) · France (3) · United Kingdom (3) · Germany (2) · Italy (2) · Spain (2) · Taiwan (2) · Australia (1) · Hong Kong (1) · Japan (1) · Netherlands (1) · Poland (1) · Romania (1) · Russia (1)
Luana Guimaraes De Sousa, MD (1) · Min-Hee Ryu, Dr. (1) · Sunil Sharma, MD, FACP (1) · Yoon-Koo Kang, MD, PhD (1)